县级医院恶性肿瘤患者QTc间期延长的风险分层管理及抗肿瘤治疗策略综述

A Summary of Risk Stratification Management and Anti-Tumor Treatment Strategies for Patients with Malignant Tumor in County Hospitals with QTc Interval Prolongation

摘要: 随着肿瘤心脏病学的发展，QTc间期延长已成为恶性肿瘤患者治疗中不可忽视的安全隐患，尤其在基层县级医院反复住院、多药联用的复杂背景下，其管理更具挑战。本文系统总结了肿瘤患者QTc间期延长的发生机制，并结合ACC/AHA及ESC肿瘤心脏病学指南，提出了统一的四级危险分层标准。在此基础上，立足县级医院的设备与人力资源实际，构建了包含入院初筛、动态监测、危急值处置、交接班台账及多学科简易协作的可落地分级管理制度。针对不同风险层级，详细阐述了化疗、靶向、免疫及内分泌药物的续用、减量与停药策略，并讨论了合并低钾低镁、心衰、房颤等高危因素时的个体化调整细则。同时，整理了电解质管理、药物精简等基层可执行预防干预策略，对比了现有国内外指南的基层适用性并给出了改良建议，以期为县级医院肿瘤内科提供一套系统、实用的QTc间期风险管理与抗肿瘤治疗决策路径。

Abstract: With the advancement of cardio-oncology, QTc interval prolongation has become a non-negligible safety hazard during the treatment of patients with malignant tumors. Its clinical management faces greater challenges, especially in primary county-level hospitals under complicated clinical scenarios involving repeated hospitalizations and combined multiple medications. This paper systematically summarizes the pathogenetic mechanisms of QTc interval prolongation in oncologic patients, and establishes a unified four-tier risk stratification criterion in accordance with the ACC/AHA and ESC guidelines on cardio-oncology. Based on the actual equipment and human resource conditions of county-level hospitals, a practicable hierarchical management system is constructed, covering admission initial screening, dynamic electrocardiographic monitoring, critical value disposal, shift handover ledger management and simplified multidisciplinary collaboration modes. For patients at distinct risk levels, detailed strategies for continuous administration, dose reduction and discontinuation of chemotherapy, targeted therapy, immunotherapy and endocrine agents are elaborated. Individualized adjustment protocols are further discussed for patients complicated with high-risk conditions such as hypokalemia, hypomagnesemia, heart failure and atrial fibrillation. In addition, executable grassroots prevention and intervention measures including electrolyte regulation and rational simplification of concomitant medications are sorted out. The applicability of existing domestic and international guidelines in primary medical settings is compared, and corresponding optimized suggestions are put forward. This study aims to provide systematic and practical decision-making pathways for QTc interval risk management and anti-tumor therapy formulation for the department of medical oncology in county-level hospitals.